DURECT CORP: management transactions · United States · SEC (Form 4)

About DURECT CORP

DURECT Corp. is a United States biopharmaceutical company listed on the NASDAQ market (ticker: DRRX), with headquarters in Cupertino, California, United States. For French-speaking investors in Europe, it should be viewed as a small-cap biotech focused on research and development rather than as a large, commercial-stage pharmaceutical company. DURECT originally built its business around drug-delivery technologies and controlled-release formulations, and over time it has increasingly concentrated its portfolio on more differentiated development programs, especially in epigenetic therapy. The company’s core activity is now centered on developing drug candidates intended to address serious diseases, with a strong emphasis on acute liver injury and related inflammatory conditions. DURECT’s lead program is larsucosterol, a molecule designed to modulate DNA methylation and potentially correct biological dysregulation involved in severe disease states. This positions the company in a scientifically specialized, high-risk, high-reward niche. If clinical and regulatory execution is successful, the upside can be meaningful; if not, the downside risk is also substantial, which is typical of late-stage biotech names. From a competitive standpoint, DURECT operates in a crowded environment that includes large pharmaceutical companies and numerous specialized biotechnology peers working in liver disease, epigenetics, and novel therapeutic mechanisms. Its relative strength lies in its focused scientific platform and the concentration of resources on a small number of priority programs. The trade-off is significant reliance on clinical data, regulatory interactions with the FDA, and access to capital. For investors, that means the company’s valuation can be highly sensitive to binary events. Alongside its development pipeline, DURECT has also had legacy product and non-core asset activities, but its recent public messaging shows a clear strategic emphasis on advancing its clinical assets and maximizing pipeline value. In 2025, the company issued multiple financial and business updates, and in July 2025 it announced an acquisition agreement with Bausch Health, a major strategic development that materially changed the investment case and the medium-term corporate outlook. DURECT also disclosed a Nasdaq minimum bid-price compliance issue, which is important context for equity investors because it highlights the pressure often faced by small-cap biotech stocks. In short, DURECT Corp. combines a differentiated scientific history, a narrow but potentially valuable pipeline, and a fragile market position. For a European investor, it is best understood as a speculative biotechnology story on NASDAQ in the United States, driven by clinical catalysts, regulatory milestones, and M&A optionality.